Items Tagged ‘Yervoy’

October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

By

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy


September 14th, 2015

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer

By

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday at the 16th World Conference on Lung Cancer in Denver, CO. Lung cancer remains the leading cause of cancer-related deaths worldwide. […]

View full entry

Tags: clinical trial, CTLA4, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, Yervoy


June 29th, 2015

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

By

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England Journal of Medicine. Standard treatment for advanced melanoma typically […]

View full entry

Tags: advanced melanoma, ipilimumab, Melanoma, News, nivolumab, opdivo, Stage III Melanoma, Stage IV Melanoma, Yervoy


June 1st, 2015

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer

By

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Prostate cancer is a hormonally sensitive disease that can […]

View full entry

Tags: castration resistant, crpc, glafolivec, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Prostvac, Yervoy


April 20th, 2015

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is less common than non-melanoma skin cancer, but tends to be much more aggressive. What makes melanoma so dangerous is that it […]

View full entry

Tags: advanced melanoma, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, pembrolizumab, Stage III Melanoma, Stage IV Melanoma, Yervoy


February 6th, 2015

Yervoy® Improves Treatment of Stage III Melanoma

By

CancerConnect News: The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with stage III melanoma appears promising, demonstrating an improvement by delaying cancer recurrence and improving survival. Skin cancer is the most common form of cancer in the United States, with more than one million new cases each year. Skin cancer is often […]

View full entry

Tags: ipilimumab, Melanoma, News, stage 3 melanoma, Stage III Melanoma, Yervoy


December 8th, 2014

Yervoy® May be Beneficial in Uveal Melanoma

By

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR) 2014 International Congress, in Zurich, Switzerland. Uveal melanoma is the most common cancer of the eye in adults, and the […]

View full entry

Tags: ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, uveal melanoma, Yervoy


November 24th, 2014

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures

By

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.  MSK was at the forefront of the clinical research that brought this CTLA-4 […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy


November 14th, 2014

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

By

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each year.2 Rates of melanoma—the deadliest form of skin cancer—are on the rise,2 particularly […]

View full entry

Tags: anti-PD-1, basal cell, General Skin Cancer, keytruda, Melanoma, News, pembrolizumab, Recurrent Melanoma, Skin Cancer, Skin Cancer Overview, Stage III Melanoma, Stage IV Melanoma


November 12th, 2014

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma

By

(CancerConnect) Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Patients in the clinical trial who got the combined therapies also […]

View full entry

Tags: gm-csf, ipilimumab, Melanoma, News, Recurrent Melanoma, sargramostim, Stage IV Melanoma, Yervoy


June 4th, 2014

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients

By

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated in metastatic melanoma patients and showed promising tumor response and duration of response. Adverse events previously observed with Yervoy were found to be reversible with proper management. IDO1 […]

View full entry

Tags: IDO1 inhibitor, INCB024360, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy